亿帆医药：子公司收到褪黑素颗粒药品注册受理通知书

Core Viewpoint - The company has received a notice of acceptance for the registration application of melatonin granules, aimed at improving sleep difficulties in children with neurodevelopmental disorders aged 6-15, making it the first domestic generic application in this category [1] Group 1 - The full subsidiary, Suzhou Yifan Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration on August 5, 2025 [1] - Melatonin granules are specifically designed for children aged 6-15 with neurodevelopmental disorders [1] - According to IQVIA, the global sales of melatonin granules are projected to reach 20.09 million USD in 2024 [1]